AAV Formulation and SEC Analysis for DNA Impurity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to effectively characterize nucleic acid impurities in adeno-associated virus (AAV) vectors and minimize leakage of packed DNA during storage conditions such as freeze-thaw cycles, leading to degradation and reduced stability of AAV biopharmaceuticals.
Innovation Solution
The use of size exclusion chromatography (SEC) combined with spectrophotometry for impurity characterization, and the application of stabilizing compositions containing excipients like sugars, amino acids, and non-ionic surfactants to protect AAV vectors from DNA leakage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If AAV vectors are stored as frozen solutions, then product stability is improved, but degradation occurs during freeze-thaw cycles producing DNA impurities
Solution Approach 1:
The patent applies preliminary action by formulating AAV products with stabilizing excipients (sugars, amino acids, surfactants) before storage to prevent degradation during freeze-thaw cycles. This preemptive formulation approach reduces DNA impurity generation without requiring post-degradation cleanup
Solution Approach 2:
The patent converts the harmful effect of freeze-thaw cycles into a beneficial characterization opportunity by using these cycles to deliberately generate controlled degradation products that can then be quantified and used to establish stability specifications and shelf-life predictions
2Device complexity
If conventional characterization methods are used, then simplicity is maintained, but nucleic acid impurities cannot be effectively identified or quantified
Solution Approach 1:
The patent segments the characterization process into distinct functional modules: size exclusion chromatography for separation based on molecular size, followed by spectrophotometric detection for quantification. This segmentation allows each module to be optimized independently while maintaining overall method accessibility
Solution Approach 2:
The patent introduces size exclusion chromatography as an intermediary separation step between the AAV sample and direct detection. This intermediary enables selective separation of nucleic acid impurities from intact AAV particles based on size differences, allowing subsequent accurate quantification without interference
3Device complexity
If no stabilizing formulation is used, then formulation complexity is reduced, but DNA leakage from AAV vectors increases during storage
Solution Approach 1:
The patent employs composite formulation strategies by combining multiple types of excipients (sugars for cryoprotection, amino acids for protein stabilization, non-ionic surfactants for membrane protection) to create a synergistic stabilizing system that addresses multiple degradation pathways simultaneously
Solution Approach 2:
The patent applies parameter changes by optimizing excipient concentrations, pH, and ionic strength to create formulation conditions that maximize AAV stability. Systematic variation of these parameters identifies optimal conditions that minimize DNA leakage while maintaining product efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid, reliable, and sensitive identification of DNA impurities and minimizes DNA leakage from AAV vectors, enhancing the stability and quality of AAV biopharmaceuticals under various storage conditions.
Implementation Method 1
contacting the sample containing AAV vectors to a size-exclusion chromatography (SEC) column
Implementation Method 2
measuring the absorbance of the at least one eluent at 280 nm using the spectrophotometer and measuring the absorbance ratio of the at least one eluent at 260/280 nm
Data Source
AI summary
Methods for characterizing DNA impurities in adeno-associated virus (AAV) samples or biopharmaceuticals are provided including the use of size exclusion chromatography and spectrophotometry. Methods and compositions are also provided to minimize leakage of packed DNA from AAV vector including the use of excipients, such as a sugar, an amino acid, a surfactant, or polyols.